Naltrexone can cause a false positive on a standard urine drug screen, specifically for oxycodone. The culprit is not naltrexone itself but one of its breakdown products, a metabolite called noroxymorphone, which is structurally similar enough to oxycodone’s own metabolites to trick certain screening tests. This is an underappreciated problem for people taking naltrexone for alcohol or opioid use disorder, and it can create real complications in clinical, legal, and workplace settings.
Why an Opioid Blocker Looks Like an Opioid
Naltrexone is an opioid antagonist. It works by binding to opioid receptors in the brain, especially the mu-opioid receptor, without activating them. That binding blocks the euphoric effects of both opioids and alcohol, which is why the drug is prescribed to help people in recovery from either substance.
Once you swallow naltrexone, your liver starts breaking it down. The primary metabolite is 6-beta-naltrexol, which is well known and well studied. But naltrexone also produces lesser-known metabolites, including noroxymorphone. That name might ring a bell: oxymorphone is an opioid painkiller, and noroxymorphone is also a metabolite of oxycodone. When a screening test detects noroxymorphone in your urine, it cannot tell whether that molecule came from naltrexone or from oxycodone. The test just sees a shape it recognizes and flags it as positive.
A published case report documented exactly this scenario in a patient stabilized on oral naltrexone who repeatedly tested positive for oxycodone on standard urine drug screens. Confirmatory testing later proved that the noroxymorphone came from naltrexone, not from any illicit opioid use.1PubMed Central. Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications The patient had not taken oxycodone at all. The screening test was simply fooled.
How Screening Tests Get Tricked
To understand why this happens, it helps to know that most initial drug screens use a technology called immunoassay. These tests work by using antibodies designed to recognize a particular drug or class of drugs. The antibodies bind to molecules with a certain shape, and if enough binding occurs, the test reads as positive. Immunoassays are fast and cheap, which is why they are the default for workplace testing, emergency departments, pain clinics, and substance use treatment programs.
The trade-off for speed and low cost is precision. Immunoassay antibodies are not perfectly selective. They are designed to recognize a target molecule, but they will also latch onto other molecules that look similar enough. This phenomenon, called cross-reactivity, is one of the most common reasons for false-positive results across every drug panel, not just opioids.2PubMed Central. Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records A large review of urine drug screen immunoassays confirmed that many cross-reactivities exist with unrelated compounds, and these can impair patient care when results are taken at face value.3PubMed. False-positive interferences of common urine drug screen immunoassays: a review
In the case of naltrexone, the specific immunoassay panel that gets fooled is the oxycodone screen. The antibodies in that panel are built to detect oxycodone and its metabolites, including noroxymorphone. When naltrexone’s noroxymorphone shows up in the urine, those antibodies bind to it and the test reads positive. From the test’s perspective, there is no difference between noroxymorphone from naltrexone and noroxymorphone from oxycodone.
What Confirmatory Testing Actually Proves
When a screening test comes back positive, the standard next step is confirmatory testing. This second-tier test uses a different technology entirely, typically liquid chromatography paired with mass spectrometry. Instead of relying on antibody shape-matching, confirmatory tests identify molecules by their exact mass and chemical signature. They can distinguish between noroxymorphone that exists alongside oxycodone’s other metabolites (which would indicate real oxycodone use) and noroxymorphone that appears alone (which points to naltrexone as the source).
In the documented case report, confirmatory testing was negative for oxycodone and its two primary metabolites. The only opioid-related substance detected was noroxymorphone, which was consistent with naltrexone metabolism rather than oxycodone use.1PubMed Central. Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications This is the key forensic detail: oxycodone produces noroxymorphone, but it also produces oxymorphone and other identifiable compounds. If none of those companion metabolites are present, the noroxymorphone almost certainly came from naltrexone.
The problem is that confirmatory testing is not always ordered automatically. In many clinical settings and virtually all workplace testing protocols, the initial screen result is what drives immediate decisions. A patient in a pain management program might be dismissed from care. A person on probation might face legal consequences. The confirmatory test that would clear them may not happen unless someone specifically requests it and understands why it matters.
Which Drug Panels Are Affected
Based on the available evidence, the false-positive risk from naltrexone is specific to the oxycodone panel. Standard opiate immunoassays, which screen for morphine and codeine, are a separate test and are not reported to cross-react with naltrexone’s metabolites in the same way. Similarly, amphetamine, benzodiazepine, and cannabis panels are not implicated.
This distinction matters because not all drug screens test for the same things. A basic five-panel test screens for amphetamines, cannabinoids, cocaine, opiates, and phencyclidine (PCP). It does not include a separate oxycodone panel. Many expanded panels, such as the 10- or 12-panel screens common in pain clinics and substance use treatment programs, add oxycodone, benzodiazepines, methadone, and other specific drugs. If you are taking naltrexone and being tested on a basic five-panel, the false-positive risk is lower because oxycodone-specific screening is not part of the test. But if you are in a program that uses an expanded panel, the oxycodone screen is exactly where the problem surfaces.
The irony is hard to miss. Naltrexone is prescribed specifically to help people in recovery from opioid use disorder. The patients most likely to be on naltrexone are also the patients most likely to be subjected to expanded drug panels that include oxycodone screening. The very medication meant to support their recovery can generate a test result that looks like relapse.
The Role of the Specific Assay Brand
Not all immunoassays behave identically. Different manufacturers design their antibodies with slightly different binding profiles, and they set different concentration cutoffs for what counts as a positive result. This means the same urine sample can test positive on one brand of oxycodone immunoassay and negative on another.
Research on a related opioid antagonist, naloxone (the drug in Narcan), demonstrated the same principle. Some oxycodone immunoassays cross-react with naloxone and generate false positives, while others do not. The issue was described as “assay-specific and cutoff-dependent,” and researchers recommended that laboratories choose their assays and cutoffs carefully to reduce the chance of false-positive oxycodone results for patients on opioid-related medications.4Clinical Chemistry. Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone
A study of the CEDIA buprenorphine assay showed a parallel issue: about 1.1% of patient urine samples tested falsely positive for buprenorphine, and the false-positive rate dropped substantially when the cutoff concentration was raised.5PubMed Central. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids The takeaway for naltrexone is the same: whether you get a false positive depends partly on which brand of test your lab happens to use and where they set the threshold.
This variability is frustrating because patients and even many clinicians have no control over which assay their testing facility uses. You cannot look at a drug test result and know whether it was run on an assay with high or low cross-reactivity for noroxymorphone. The test report does not typically disclose this information, and most people would not know what to do with it even if it did.
What to Do If You Are on Naltrexone and Facing Drug Testing
If you are prescribed naltrexone and you know you will be subject to drug screening, whether for work, court, a pain management program, or a substance use treatment program, there are several practical steps worth taking.
- Disclose proactively: Tell the testing provider, your prescriber, or your medical review officer (the person who interprets workplace drug test results) that you are taking naltrexone before the test. This allows them to flag the sample for potential cross-reactivity and ensures that a positive oxycodone screen is interpreted in context rather than taken at face value.
- Request confirmatory testing: If a screen comes back positive for oxycodone, insist on confirmatory testing by mass spectrometry. This test can distinguish between noroxymorphone from naltrexone and actual oxycodone metabolites. In most regulated testing programs, you have the right to request this.
- Keep documentation: Carry a copy of your prescription or have your prescriber provide a letter confirming your naltrexone use. A prescription record is the simplest way to establish that a positive result has a legitimate pharmaceutical explanation.
- Ask about the panel: Find out whether your test includes a separate oxycodone panel. If you are only being screened on a basic five-panel, the risk of this particular false positive is much lower.
None of this is your responsibility in any moral sense. The testing infrastructure should account for prescribed medications that cross-react. But in practice, the system often puts the burden on the individual to explain a result that the test itself generated incorrectly.
Low-Dose Naltrexone and Drug Testing
Low-dose naltrexone, often abbreviated LDN, is used off-label for conditions like chronic pain and autoimmune disorders at doses typically ranging from 1 to 5 milligrams per day, compared to the standard 50 mg daily dose for alcohol or opioid use disorder. A reasonable question is whether these much smaller doses produce enough noroxymorphone to trigger a false positive.
The published evidence on this specific question is thin. The documented false-positive case involved standard-dose oral naltrexone, and it is unclear whether the lower metabolite levels from LDN would cross the immunoassay threshold for a positive result.1PubMed Central. Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications The answer likely depends on the same assay-specific and cutoff-dependent factors that determine cross-reactivity at any dose. A low-sensitivity assay with a higher cutoff might not flag the smaller amount of noroxymorphone from a 4.5 mg dose. A more sensitive assay might.
If you are on LDN and concerned about testing, the same practical advice applies: disclose, document, and request confirmatory testing if needed. The risk may be lower, but it is not zero, and no one has studied it rigorously enough to quantify.
Extended-Release Naltrexone Versus Daily Oral Doses
Naltrexone comes in two forms: a daily oral tablet and a monthly extended-release injection marketed as Vivitrol. The injection delivers a sustained dose over about four weeks. From a drug-testing standpoint, the relevant question is whether the extended-release form produces different metabolite profiles or different risks of false positives compared to the daily pill.
Both formulations produce the same metabolites, including noroxymorphone. The extended-release form maintains more stable blood levels over time, which could mean more consistent (rather than fluctuating) levels of noroxymorphone in the urine. Whether this raises or lowers the false-positive risk is speculative. The published case documentation focuses on oral naltrexone, and comparable case reports for the injectable form have not received the same attention in the literature. The safest assumption is that both forms carry the risk, because both produce the same metabolite through the same biochemical pathway.
Other Medications That Cause Similar Problems
Naltrexone is far from the only medication that causes false positives on drug screens. Cross-reactivity is a systemic issue with immunoassay-based testing, and it affects a surprisingly wide range of common drugs.
Certain quinolone antibiotics, for example, can trigger false-positive opiate results. A study testing multiple quinolones across four commercial immunoassay platforms found that levofloxacin and ofloxacin caused false positives on all four assays tested, while other quinolones tripped specific brands.6JAMA. Quinolones and False-Positive Urine Screening for Opiates by Immunoassay Technology These are common antibiotics prescribed for urinary tract infections and respiratory infections, and few patients or clinicians are aware they can affect drug test results.
Over-the-counter cold medications containing dextromethorphan can trigger false positives for PCP. Certain antidepressants, particularly sertraline and trazodone, have been documented to cause false positives on various panels. Proton pump inhibitors, widely used for acid reflux, have been linked to false-positive THC (cannabis) results on some assays. The point is not to catalog every possible interaction but to underscore that a positive screening result, on any panel, for any drug, should never be treated as definitive without confirmatory testing.
Why This Matters for Substance Use Treatment
The clinical context makes the naltrexone false-positive problem especially consequential. People prescribed naltrexone for opioid use disorder are often in structured treatment programs that use frequent urine drug screens as a cornerstone of monitoring. A positive oxycodone result in that setting is not a neutral event. It can lead to discharge from the program, loss of take-home medication privileges (for patients on other medications simultaneously), escalation to more restrictive treatment settings, or referral to law enforcement in jurisdictions where drug court mandates testing.
For someone working hard at recovery, a false positive caused by the medication prescribed to support that recovery is more than an inconvenience. It can erode the trust between patient and provider, create legal jeopardy, and even discourage continued medication adherence if the patient starts to see the drug itself as a source of problems. Clinicians who prescribe naltrexone should be aware of this cross-reactivity and should proactively communicate with testing facilities and treatment teams. The published recommendation is clear: when a patient on naltrexone tests positive for oxycodone, confirmatory testing should be conducted to rule out alternative opioids before any clinical or legal decisions are made.1PubMed Central. Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications
The Broader Problem with Taking Screening Results at Face Value
Drug screening immunoassays were never designed to be the final word. They are a first-pass filter meant to identify samples worth investigating further. The entire architecture of drug testing assumes a two-step process: screen first with a fast, cheap immunoassay, then confirm any positive result with a more precise analytical method. In practice, though, the second step often does not happen. Cost, logistics, time pressure, and simple ignorance about cross-reactivity all contribute to a system where screening results are frequently treated as conclusive.
A large-scale analysis of electronic health records found that cross-reactivity in urine drug screens led to false positives that impaired patient care, reinforcing the idea that this is not a rare edge case but a routine limitation of the technology.2PubMed Central. Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records For naltrexone specifically, the evidence that noroxymorphone fools oxycodone panels is documented and reproducible. The gap is not in the science but in how the science gets applied at the point of care, in the courtroom, or in the HR office.
If you are a clinician, the lesson is straightforward: learn which medications your patients are on before interpreting a drug screen, and order confirmatory testing when a result does not match the clinical picture. If you are a patient, the lesson is equally simple but harder to act on: know your rights, document your prescriptions, and do not accept a screening result as proof of anything until it has been confirmed by a method that can tell the difference between your medication and the drug you are being accused of taking.